Ads
related to: what do sglt2 inhibitors do for kidney failure treatment- Screening & Diagnosis
Learn About Screening &
Diagnosis Here.
- Dosing
Medication Dosing Information
For Healthcare Professionals.
- Resources
Discover Resources For You
And Your Patients.
- Savings & Access
Treatment Savings & Access
For Your Patients.
- Screening & Diagnosis
Search results
Results From The WOW.Com Content Network
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
SGLT2 is a member of the sodium glucose cotransporter family, which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. [6] SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. [7]
Previous studies have found that SGLT2 inhibitors appear to lower HbA1c less in patients with worse kidney function.” “GLP-1 agonists appear to be less affected by this interaction,” he added.
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
SGLT2 inhibitors, also called gliflozins, [14] are used in the treatment of type 2 diabetes. SGLT2 is only found in kidney tubules and in conjunction with SGLT1 resorbs glucose into the blood from the forming urine. By inhibiting SGLT2, and not targeting SGLT1, glucose is excreted which in turn lowers blood glucose levels.
It is indicated in adults for the treatment of symptomatic chronic heart failure; [13] and it is indicated in adults for the treatment of chronic kidney disease. [ 13 ] Empagliflozin lowers risk of hospitalization and death in people with reduced heart function, when added to standard heart failure treatment with or without type 2 diabetes.
Ads
related to: what do sglt2 inhibitors do for kidney failure treatment